Search Result

Results for "

Diabetic mice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Adenosine Receptor (1) Akt (1) Aldose Reductase (2) Amino Acid Decarboxylase (1) Aminopeptidase (1) AMPK (4) Amylases (1) Androgen Receptor (1) Antibiotic (1) Apoptosis (5) Autophagy (2) Bacterial (2) Bombesin Receptor (1) Bradykinin Receptor (1) Calcium Channel (1) CaSR (2) CXCR (1) Dipeptidyl Peptidase (1) Drug Isomer (1) Endogenous Metabolite (6) ERK (2) Ferroptosis (1) Free Fatty Acid Receptor (2) GABA Receptor (2) GCGR (2) GLP Receptor (1) Glutathione Peroxidase (1) Glycosidase (6) HBV (3) Histamine Receptor (2) Histone Demethylase (2) HIV (1) Insulin Receptor (1) Interleukin Related (2) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) Mineralocorticoid Receptor (1) MMP (2) Neprilysin (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (2) Parasite (1) Phosphatase (1) Phosphorylase (1) PKC (1) Potassium Channel (1) PPAR (10) Reactive Oxygen Species (1) SGLT (4) SPFH Protein Superfamily (1) Tie (2) TNF Receptor (2)
By Research Areas:	Cancer (13) Cardiovascular Disease (3) Endocrinology (3) Infection (9) Inflammation/Immunology (17) Metabolic Disease (53) Neurological Disease (10)

By Targets:

11β-HSD (1)

Adenosine Receptor (1)

Akt (1)

Aldose Reductase (2)

Amino Acid Decarboxylase (1)

Aminopeptidase (1)

AMPK (4)

Amylases (1)

Androgen Receptor (1)

Antibiotic (1)

Apoptosis (5)

Autophagy (2)

Bacterial (2)

Bombesin Receptor (1)

Bradykinin Receptor (1)

Calcium Channel (1)

CaSR (2)

CXCR (1)

Dipeptidyl Peptidase (1)

Drug Isomer (1)

Endogenous Metabolite (6)

ERK (2)

Ferroptosis (1)

Free Fatty Acid Receptor (2)

GABA Receptor (2)

GCGR (2)

GLP Receptor (1)

Glutathione Peroxidase (1)

Glycosidase (6)

HBV (3)

Histamine Receptor (2)

Histone Demethylase (2)

HIV (1)

Insulin Receptor (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (2)

Mineralocorticoid Receptor (1)

MMP (2)

Neprilysin (1)

NF-κB (1)

Nuclear Hormone Receptor 4A/NR4A (1)

Nucleoside Antimetabolite/Analog (1)

Opioid Receptor (2)

Parasite (1)

Phosphatase (1)

Phosphorylase (1)

PKC (1)

Potassium Channel (1)

PPAR (10)

Reactive Oxygen Species (1)

SGLT (4)

SPFH Protein Superfamily (1)

Tie (2)

TNF Receptor (2)

By Research Areas:

Cancer (13)

Cardiovascular Disease (3)

Endocrinology (3)

Infection (9)

Inflammation/Immunology (17)

Metabolic Disease (53)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-N7515

Pinocembrin chalcone 2',4',6'-Trihydroxychalcone	Bacterial AMPK	Infection Metabolic Disease Inflammation/Immunology
Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .

HY-103290

R715	Bradykinin Receptor	Others
R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice .

HY-N7912

Pterosin A (2S)-Pterosin A	Others	Metabolic Disease
Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .

HY-116193

5-PAHSA	Endogenous Metabolite	Neurological Disease Metabolic Disease Inflammation/Immunology
5-PAHSA increases insulin sensitivity, and has orally active anti-inflammatory and neuroprotective effects in mice HFD-induced diabetes mice. 5-PAHSA can be used for research of neurological dysfunction in diabetics .

HY-N0546

Ligustroflavone Nuezhenoside	CaSR	Metabolic Disease
Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice .

HY-146280

mGAT3/4-IN-1	GABA Receptor	Neurological Disease Metabolic Disease
mGAT3/4-IN-1 (compound 19b) is a potent mGAT3/mGAT4 inhibitor, with pIC₅₀ values of 5.31 and 5.24, respectively. mGAT3/4-IN-1 exhibits a significant tactile allodynia reduction in diabetic neuropathic mice .

HY-118113

BVT-116429	11β-HSD	Others
BVT-116429 is an 11βHSD1 inhibitor with the activity of increasing adiponectin concentration and improving glucose homeostasis in diabetic mice. BVT-116429 can increase plasma adiponectin levels in diabetic KKAy mice, reduce basal insulin levels, and reduce fasting blood glucose levels after 10 days of inhibition, similar to the effect of rosiglitazone.

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

HY-125327

YM-543	SGLT	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-N3960

Glycyrin	PPAR Bacterial	Infection Metabolic Disease
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-119519

OB-2	SPFH Protein Superfamily	Neurological Disease
OB-2 is a STOML3 oligomerization blocker. OB-2 reverses pathological mechanical hypersensitivity. OB-2 can be used for research of painful diabetic neuropathy in mice .

HY-N2189

Swertisin 1 Publications Verification	Adenosine Receptor HBV SGLT	Infection Neurological Disease Inflammation/Immunology
Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice .

HY-111603

Calcium dobesilate 1 Publications Verification	Apoptosis	Metabolic Disease Inflammation/Immunology
Calcium dobesilate is a vascular protector with oral activity that can clear hydroxyl free radicals, with an IC₅₀ of 1.1 pM. Calcium dobesilate has antioxidant activity and helps to reduce oxidative stress and inflammation in the retinas of diabetic mice. Calcium dobesilate can be used to study chronic venous diseases, diabetic retinopathy, and the occurrence of hemorrhoids, among other conditions .

HY-105416

Calphostin C 1 Publications Verification UCN-1028C	Antibiotic PKC Apoptosis	Metabolic Disease Cancer
Calphostin C is a highly selective PKC inhibitor (IC₅₀=0.05 μM) and tumor apoptosis inducer. Calphostin C competitively binds to PKC and inhibits PKC-mediated phosphorylation signal transduction. Calphostin C restores Na+/K+ ATPase activity in the sciatic nerve of diabetic mice and improves neuropathy. Calphostin C can be used in the study of anti-tumor and diabetic complications .

HY-14447

Bilastine	Histamine Receptor	Inflammation/Immunology Endocrinology
Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system .

HY-N0546R

Ligustroflavone (Standard)	CaSR	Metabolic Disease
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone. This product is intended for research and analytical applications. Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice .

HY-120912

Gingerenone A	Keap1-Nrf2 Glutathione Peroxidase Ferroptosis	Metabolic Disease Inflammation/Immunology Cancer
Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice .

HY-N9536

Cinnamtannin A2	GLP Receptor	Metabolic Disease
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect .

HY-117172

CP320626	Phosphorylase	Metabolic Disease
CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC₅₀=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .

HY-N3015

Bruceine E	Others	Metabolic Disease
Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .

HY-162893

SX29	Glycosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-N11286

Tridocosahexaenoylglycerol TG-DHA; Meganol D	Others	Neurological Disease Metabolic Disease Inflammation/Immunology
Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .

HY-173130

α-Glucosidase-IN-86	Glycosidase	Metabolic Disease Inflammation/Immunology
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC₅₀ of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .

HY-14447S1

Bilastine-d4	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology Endocrinology
Bilastine-d₄ is deuterium labeled Bilastine. Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system .

HY-163066

α-Glucosidase-IN-44	Glycosidase	Metabolic Disease
α-Glucosidase-IN-44 (compound IT4) is an inhibitor of α-glucosidase with IC₅₀ value of 2.35 μM. α-Glucosidase-IN-44 has an oral activity. α-Glucosidase-IN-44 suppresses fasting blood glucose levels in diabetic mice .

HY-P5489

IGRP(206-214)	Phosphatase	Others
IGRP(206-214) is a biological active peptide. (This peptide corresponds to residues 206–214 of murine islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP). This peptide is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice.)

HY-124373

ND-336	MMP	Metabolic Disease
ND-336 is a selective inhibitor of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-14, with K_is of 85, 150, and 120 nM, respectively. ND-336 accelerates diabetic wound healing in mice by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-101064

Fmoc-leucine N-FMOC-leucine; NPC 15199; NSC 334290	PPAR	Metabolic Disease
Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-66009R

Epalrestat (Standard)	Aldose Reductase	Metabolic Disease Inflammation/Immunology Cancer
Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .

HY-66009

Epalrestat 3 Publications Verification ONO2235	Aldose Reductase	Metabolic Disease Inflammation/Immunology Cancer
Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .

HY-W201317

E17241	PPAR	Metabolic Disease
E17241 is an inducer of the expression of ABCA1 that increases the protein levels of ABCA1 in RAW 264.7 macrophages. E17241 is also an agonist of peroxisome proliferator-activated receptors (PPARs ). E17241 decreases plasma glucose levels and body weight in KKAy diabetic mice fed a high-fat and high-glucose (HFHG) diet .

HY-N5097

13-Oxo-9E,11E-octadecadienoic acid	PPAR	Metabolic Disease
13-Oxo-9E,11E-octadecadienoic acid, an isomer of 9-oxo-ODA, is a potent PPARα activator derived from tomato juice. 13-Oxo-9E,11E-octadecadienoic acid decreases plasma and hepatic triglyceride in obese diabetic mice .

HY-121798

TZD18	PPAR	Metabolic Disease
TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC₅₀ values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .

HY-119678

Fortunellin	AMPK Keap1-Nrf2	Cardiovascular Disease Metabolic Disease
Fortunellin, is a flavonoid, that can be isolated from the fruits of Fortunella margarita (kumquat). Fortunellin exhibits little toxicity to mice and suppresses inflammation and ROS generation in H9C2 cells induced by LPS. Fortunellin protects against fructose-induced inflammation and oxidative stress by enhancing AMPK/Nrf2 pathway. Fortunellin can be used for diabetic cardiomyopathy research .

HY-N11286R

Tridocosahexaenoylglycerol (Standard)	Others	Neurological Disease Metabolic Disease Inflammation/Immunology
Tridocosahexaenoylglycerol (Standard) is the analytical standard of Tridocosahexaenoylglycerol. This product is intended for research and analytical applications. Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-101064S3

Fmoc-leucine-d10	PPAR	Metabolic Disease
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-101064S2

Fmoc-leucine-d3 N-FMOC-leucine-d₃; NPC 15199-d₃; NSC 334290-d₃	PPAR	Metabolic Disease
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-138842

DDN	Insulin Receptor Akt ERK	Metabolic Disease
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .

HY-154985

DSO-5a	PPAR Bombesin Receptor ERK	Metabolic Disease
DSO-5a is a potent, selective, orally active BB₃ agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates ppar-γ activity through BB₃ and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research .

HY-113365

Cholestenone 4-Cholesten-3-one	Endogenous Metabolite	Infection Metabolic Disease
Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice .

HY-N6020A

(+)-Butin	Others	Others
(+)-Butin is the R enantiomer of Butin. Butin is a major biologically active flavonoid isolated from the heartwood of Dalbergia odorifera, with strong antioxidant, antiplatelet and anti-inflammatory activities .

HY-113365R

Cholestenone (Standard)	Endogenous Metabolite	Infection Metabolic Disease
Clebopride (malate) (Standard) is the analytical standard of Clebopride (malate). This product is intended for research and analytical applications. Clebopride malate is a dopamine antagonist used in the study of functional gastrointestinal disorders.

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-134314

8-Nitro-cGMP	Autophagy Endogenous Metabolite Nucleoside Antimetabolite/Analog	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
8-Nitro-cGMP is an electrophilic second messenger of redox signaling that can form a protein-S-cGMP adduct in s-guanylation process. 8-Nitro-cGMP is an autophagy inducer. 8-Nitro-cGMP promotes RANKL-induced osteoclast differentiation from macrophages. 8-Nitro-cGMP has vasodilator effect, and ameliorates the vascular endothelial dysfunction in diabetic mice .

HY-19876

PL37 Debio-0827	Opioid Receptor Aminopeptidase Neprilysin	Neurological Disease Metabolic Disease
PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED₅₀ value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain .

Cat. No.	Product Name	Target	Research Area

HY-103290

R715	Bradykinin Receptor	Others
R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice .

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P5489

IGRP(206-214)	Phosphatase	Others
IGRP(206-214) is a biological active peptide. (This peptide corresponds to residues 206–214 of murine islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP). This peptide is T cells specific for proinsulin and IGRP induces diabetes in non-obese diabetic (NOD) mice.)

HY-P10580A

Vasculotide TFA	Tie	Infection Metabolic Disease Inflammation/Immunology Cancer
Vasculotide TFA, an angiopoietin-1 mimetic, is a Tie-2 activator and induces Tie-2 phosphorylation. Vasculotide has anti-inflammatiory effect and anti-permeability. Vasculotide TFA ameliorates endotoxin-induced endothelial barrier dysfunction. Vasculotide TFA promotes angiogenesis in a mouse model of diabetic ulcer. Vasculotide TFA protects mice from vascular leakage and reduces mortality in murine abdominal sepsis. Vasculotide TFA decreases microvascular leakage and improves microcirculatory perfusion in a rat model of hemorrhagic shock .

HY-P1910

BDC2.5 mimotope 1040-51	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice .